TM-Cy-TBPA
TM-Cy-TBPA is a selective inhibitor of mammalian dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) with an IC50 of 0.034 μM. TM-Cy-TBPA inhibits breast cancer cell proliferation via G2 phase arrest and apoptosis. TM-Cy-TBPA can be used for the research of metastatic breast cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C47H64F3N7O14
- Peso molecular:1008.04
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | EC50 |
0.69 μM
|
Antiproliferative activity against human MCF-7 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
Antiproliferative activity against human MCF-7 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
|
2026.07.28.741246 |
| BT-474 | EC50 |
0.48 μM
|
Antiproliferative activity against human BT-474 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
Antiproliferative activity against human BT-474 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
|
2026.07.28.741246 |
| BT-474 | EC50 |
0.54 μM
|
Antiproliferative activity against human BT-474 Clone 5 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
Antiproliferative activity against human BT-474 Clone 5 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
|
2026.07.28.741246 |
| SK-BR-3 | EC50 |
0.63 μM
|
Antiproliferative activity against human SKBr-3 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
Antiproliferative activity against human SKBr-3 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
|
2026.07.28.741246 |
| MDA-MB-468 | EC50 |
0.65 μM
|
Antiproliferative activity against human MDA-MB-468 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
Antiproliferative activity against human MDA-MB-468 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
|
2026.07.28.741246 |
| MDA-MB-231 | EC50 |
0.69 μM
|
Antiproliferative activity against human MDA-MB-231 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
Antiproliferative activity against human MDA-MB-231 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
|
2026.07.28.741246 |
| MDA-MB-453 | EC50 |
0.58 μM
|
Antiproliferative activity against human MDA-MB-453 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
Antiproliferative activity against human MDA-MB-453 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
|
2026.07.28.741246 |
TM-Cy-TBPA (0-10 μM) potently and selectively inhibits human DPAGT1 with an IC50 of 0.45 μM, shows no detectable activity against microbial lipid transferases, and exhibits no antibacterial activity[1].
TM-Cy-TBPA inhibits the proliferation of breast cancer cell lines, including the triple-negative subtype cell lines MDA-MB-231 and MDA-MB-468, with EC50 values ranging from 0.48 to 0.69 μM[1].
TM-Cy-TBPA (0.1-10 μM; 6 h) induces extremely low levels of LDH leakage in MDA-MB-231 breast cancer cells even at concentrations as high as 10 μM, confirming that cell membrane integrity is preserved[1].
TM-Cy-TBPA (0.1-10 μM; 24 h) induces G2 cell cycle arrest and mitochondria-mediated apoptosis in SKBr-3 and MDA-MB-231 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SKBr-3 and MDA-MB-231 cells
-
Concentration:0.1, 0.25, 1.0, 2.5, 10 μM
-
Incubation Time:24 h
-
Result:Increased the levels of Cyclin B1, p-CDK1(Tyr15), Wee1, BiP/GRP78, XBP1s, CHOP, cytosolic cytochrome c, cleaved caspase-3/7, and cleaved PARP, while decreasing the levels of phospho-Histone H3(Ser10) and Bcl-2.
Chemical Information
-
Peso molecular 1008.04
-
Fòrmula C47H64F3N7O14
-
SMILES
[H][C@@]1(O[C@H]2[C@H](NC(CNCC(C=C3)=CC=C3N(CC4)CCC4CNCC5=CC=C(OC(F)(F)F)C=C5)=O)CC[C@@H](C[C@@H](O)[C@@H]6[C@@H](O)[C@@H](O)[C@H](N7C(NC(C=C7)=O)=O)O6)C2)O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1NC(C)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)